In recent years, few cancer therapies have generated as much excitement as CAR T cell therapy . By reprogramming patients' own immune cells to recognize and destroy cancer, CAR T treatment has produced dramatic results in certain blood cancers. For patients with leukemia or lymphoma who had exhausted all other options, these engineered immune cells offered something rare in oncology: durable remission.

At the center of this therapy is the T cell : a white blood cell that plays a critical role in the immune system. Under normal conditions, T cells patrol the body, scanning other cells for signs of infection or abnormal behavior. When they recognize a threat, they can directly kill the affected cell or help coordinate a broader immune response. Cancer, however, often escapes this surveillance by hiding from or suppressing T cell activity.

CAR T, short for chimeric antigen receptor T cell therapy , is a form of immunotherapy that harnesses these cells and enhances their ability to recognize cancer. T cells are collected from the patient’s blood and genetically modified in the lab to express a synthetic receptor designed to recognize a specific protein on cancer cells. Once expanded to large numbers, the engineered cells are infused back into the bloodstream. This receptor acts like a molecular lock-and-key system. When a CAR T cell encounters its target antigen, it becomes activated and kills the cancer cell. Importantly, CAR T cells can continue to multiply in the body, providing ongoing immune surveillance long after infusion. In blood cancers , where malignant cells circulate through the blood and bone marrow and often share a uniform surface marker, this approach has been especially effective.

When researchers attempted to apply the same strategy to solid tumors, however, the results were far more limited. Unlike blood cancers, solid tumors grow within dense tissues rather than the circulation. CAR T cells must leave the bloodstream, penetrate physical barriers, and survive in an environment that actively suppresses immune activity. Many never reach the tumor at all. Those that do arrive encounter a hostile landscape known as the tumor microenvironment. Solid tumors are often low in oxygen and nutrients and are surrounded by signals that blunt T cell function. Over time, CAR T cells can become exhausted, losing their ability to kill cancer cells effectively.

Recognition poses another challenge. Blood cancers often display consistent surface markers that make them clear targets. Solid tumors , by contrast, are highly heterogeneous. Different cells within the same tumor may express different proteins, allowing some cancer cells to evade detection even as others are eliminated.

Rather than abandoning CAR T therapy for solid tumors , researchers are rethinking how it should be designed. The challenge is no longer simply making powerful immune cells, but helping them reach tumors, remain active once they arrive, and function within an environment that evolved to resist immune attack. This has shifted attention toward the tumor microenvironment itself , which plays an active role in shaping whether immune therapies succeed or fail. Rather than treating the tumor microenvironment as a static obstacle, researchers are rethinking CAR T therapy by engineering cells that can actively remodel suppressive conditions , resist inhibitory signals, and recruit broader immune responses, though these strategies have yet to achieve consistent clinical success.

Solid tumors account for the vast majority of cancer diagnoses, and their resistance to immunotherapy reflects their biological complexity rather than a lack of immune potential. If CAR T cells can be adapted to navigate dense tissue, survive suppressive signals, and recognize diverse cancer cells, they could expand immunotherapy beyond the blood and into the cancers that affect the most patients .

CAR T cell therapy has already transformed treatment for many blood cancers. Extending that success to solid tumors remains one of the field’s greatest challenges, but also one of its most important opportunities. Understanding how immune cells behave within solid tissue may ultimately determine whether engineered T cells can fulfill their promise across cancer as a whole.